Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Denmark's Novo Nordisk A/S (NOVO-B.KO), the world's largest maker of insulin, Wednesday posted a forecast-beating first-quarter net profit rise of 28%, helped by strong growth in sales of its diabetes drug Victoza, and raised its full-year outlook slightly.
MAIN FACTS:
-Lifts 2013 sales growth outlook slightly to 9%-11% in local currencies, from 8%-11%, while reported sales growth is now expected to be around 3 percentage points lower than growth measured in local currencies having earlier expected the figure to be 4.5 percentage points lower.
http://www.foxbusiness.com/news/2013/05/01/novo-nordisk-net-profit-up-as-insulin-sales-surge/
MAIN FACTS:
-Lifts 2013 sales growth outlook slightly to 9%-11% in local currencies, from 8%-11%, while reported sales growth is now expected to be around 3 percentage points lower than growth measured in local currencies having earlier expected the figure to be 4.5 percentage points lower.
http://www.foxbusiness.com/news/2013/05/01/novo-nordisk-net-profit-up-as-insulin-sales-surge/